We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phytopharm | LSE:PYM | London | Ordinary Share | GB00BCLY7L40 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 58.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Dec 2019 to Dec 2024
TIDMIXI
RNS Number : 2665E
IXICO plc
02 November 2015
2 November 2015
IXICO plc
Total Voting Rights
In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company') confirms that the Company's issued share capital consists of 15,215,664 ordinary shares of 50p each in issue, each with equal voting rights. No shares are held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
IXICO plc +44 20 3763 7499 Derek Hill, CEO Susan Lowther, CFO Charles Spicer, VP Corporate Development Peel Hunt LLP (Nominated Adviser and Broker) +44 20 7418 8900 James Steel Oliver Jackson Daniel Stewart & Company (Joint Broker) +44 207 776 6550 Martin Lampshire David Coffman FTI Consulting Limited (Investor Relations) +44 20 3727 1000 Simon Conway Mo Noonan Matthew Moss
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.
More information is available on www.ixico.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRUGGMWGUPAGAP
(END) Dow Jones Newswires
November 02, 2015 10:38 ET (15:38 GMT)
1 Year Phytopharm Chart |
1 Month Phytopharm Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
